Free Trial

Forsta AP Fonden Sells 28,200 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Zimmer Biomet logo with Medical background

Key Points

  • Forsta AP Fonden has reduced its holdings in Zimmer Biomet Holdings, Inc. by 29.0% in the first quarter, now owning 69,000 shares worth approximately $7.81 million.
  • Multiple analysts have adjusted their price targets for Zimmer Biomet, with Robert W. Baird lowering its target from $130.00 to $115.00 while maintaining an "outperform" rating.
  • Zimmer Biomet recently declared a quarterly dividend of $0.24 per share, translating to an annual yield of 1.0% and a payout ratio of 23.36%.
  • Looking to export and analyze Zimmer Biomet data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Forsta AP Fonden cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 29.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,000 shares of the medical equipment provider's stock after selling 28,200 shares during the quarter. Forsta AP Fonden's holdings in Zimmer Biomet were worth $7,809,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Garde Capital Inc. bought a new position in Zimmer Biomet in the 1st quarter worth about $29,000. Menard Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter worth about $30,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet in the 1st quarter worth about $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet in the 1st quarter worth about $30,000. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet in the 1st quarter worth about $35,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on ZBH shares. JMP Securities decreased their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Raymond James Financial upped their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Royal Bank Of Canada upped their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, Robert W. Baird cut their price objective on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $111.44.

Get Our Latest Stock Report on ZBH

Insiders Place Their Bets

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Up 0.9%

Shares of NYSE:ZBH traded up $0.93 during trading on Wednesday, hitting $102.75. The stock had a trading volume of 78,603 shares, compared to its average volume of 2,081,180. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The company has a market capitalization of $20.35 billion, a PE ratio of 25.03, a PEG ratio of 2.28 and a beta of 0.68. The firm's fifty day moving average is $93.71 and its 200 day moving average is $99.59. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the prior year, the company earned $2.01 EPS. The business's revenue was up 7.0% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Read More

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Should You Invest $1,000 in Zimmer Biomet Right Now?

Before you consider Zimmer Biomet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.

While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines